Lack of antiviral activity of probenecid in vitro and in Syrian golden hamsters
© The Author(s) 2023. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy..
OBJECTIVES: Antiviral interventions are required to complement vaccination programmes and reduce the global burden of COVID-19. Prior to initiation of large-scale clinical trials, robust preclinical data to support candidate plausibility are required. This work sought to further investigate the putative antiviral activity of probenecid against SARS-CoV-2.
METHODS: Vero E6 cells were preincubated with probenecid, or control media for 2 h before infection (SARS-CoV-2/Human/Liverpool/REMRQ0001/2020). Probenecid or control media was reapplied, plates reincubated and cytopathic activity quantified by spectrophotometry after 48 h. In vitro human airway epithelial cell (HAEC) assays were performed for probenecid against SARS-CoV-2-VoC-B.1.1.7 (hCoV-19/Belgium/rega-12211513/2020; EPI_ISL_791333, 2020-12-21) using an optimized cell model for antiviral testing. Syrian golden hamsters were intranasally inoculated (SARS-CoV-2 Delta B.1.617.2) 24 h prior to treatment with probenecid or vehicle for four twice-daily doses.
RESULTS: No observable antiviral activity for probenecid was evident in Vero E6 or HAEC assays. No reduction in total or subgenomic RNA was observed in terminal lung samples (P > 0.05) from hamsters. Body weight of uninfected hamsters remained stable whereas both probenecid- and vehicle-treated infected hamsters lost body weight (P > 0.5).
CONCLUSIONS: These data do not support probenecid as a SARS-CoV-2 antiviral drug.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:79 |
|---|---|
| Enthalten in: |
The Journal of antimicrobial chemotherapy - 79(2024), 1 vom: 03. Jan., Seite 172-178 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Box, Helen J [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 04.01.2024 Date Revised 04.01.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/jac/dkad362 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364865180 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364865180 | ||
| 003 | DE-627 | ||
| 005 | 20240108141710.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/jac/dkad362 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1248.xml |
| 035 | |a (DE-627)NLM364865180 | ||
| 035 | |a (NLM)37995258 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Box, Helen J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Lack of antiviral activity of probenecid in vitro and in Syrian golden hamsters |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.01.2024 | ||
| 500 | |a Date Revised 04.01.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2023. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. | ||
| 520 | |a OBJECTIVES: Antiviral interventions are required to complement vaccination programmes and reduce the global burden of COVID-19. Prior to initiation of large-scale clinical trials, robust preclinical data to support candidate plausibility are required. This work sought to further investigate the putative antiviral activity of probenecid against SARS-CoV-2 | ||
| 520 | |a METHODS: Vero E6 cells were preincubated with probenecid, or control media for 2 h before infection (SARS-CoV-2/Human/Liverpool/REMRQ0001/2020). Probenecid or control media was reapplied, plates reincubated and cytopathic activity quantified by spectrophotometry after 48 h. In vitro human airway epithelial cell (HAEC) assays were performed for probenecid against SARS-CoV-2-VoC-B.1.1.7 (hCoV-19/Belgium/rega-12211513/2020; EPI_ISL_791333, 2020-12-21) using an optimized cell model for antiviral testing. Syrian golden hamsters were intranasally inoculated (SARS-CoV-2 Delta B.1.617.2) 24 h prior to treatment with probenecid or vehicle for four twice-daily doses | ||
| 520 | |a RESULTS: No observable antiviral activity for probenecid was evident in Vero E6 or HAEC assays. No reduction in total or subgenomic RNA was observed in terminal lung samples (P > 0.05) from hamsters. Body weight of uninfected hamsters remained stable whereas both probenecid- and vehicle-treated infected hamsters lost body weight (P > 0.5) | ||
| 520 | |a CONCLUSIONS: These data do not support probenecid as a SARS-CoV-2 antiviral drug | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Probenecid |2 NLM | |
| 650 | 7 | |a PO572Z7917 |2 NLM | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 700 | 1 | |a Sharp, Joanne |e verfasserin |4 aut | |
| 700 | 1 | |a Pennington, Shaun H |e verfasserin |4 aut | |
| 700 | 1 | |a Kijak, Edyta |e verfasserin |4 aut | |
| 700 | 1 | |a Tatham, Lee |e verfasserin |4 aut | |
| 700 | 1 | |a Caygill, Claire H |e verfasserin |4 aut | |
| 700 | 1 | |a Lopeman, Rose C |e verfasserin |4 aut | |
| 700 | 1 | |a Jeffreys, Laura N |e verfasserin |4 aut | |
| 700 | 1 | |a Herriott, Joanne |e verfasserin |4 aut | |
| 700 | 1 | |a Neary, Megan |e verfasserin |4 aut | |
| 700 | 1 | |a Valentijn, Anthony |e verfasserin |4 aut | |
| 700 | 1 | |a Pertinez, Henry |e verfasserin |4 aut | |
| 700 | 1 | |a Curley, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Arshad, Usman |e verfasserin |4 aut | |
| 700 | 1 | |a Rajoli, Rajith K R |e verfasserin |4 aut | |
| 700 | 1 | |a Jochmans, Dirk |e verfasserin |4 aut | |
| 700 | 1 | |a Vangeel, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Neyts, Johan |e verfasserin |4 aut | |
| 700 | 1 | |a Chatelain, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Escudié, Fanny |e verfasserin |4 aut | |
| 700 | 1 | |a Scandale, Ivan |e verfasserin |4 aut | |
| 700 | 1 | |a Rannard, Steve |e verfasserin |4 aut | |
| 700 | 1 | |a Stewart, James P |e verfasserin |4 aut | |
| 700 | 1 | |a Biagini, Giancarlo A |e verfasserin |4 aut | |
| 700 | 1 | |a Owen, Andrew |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of antimicrobial chemotherapy |d 1981 |g 79(2024), 1 vom: 03. Jan., Seite 172-178 |w (DE-627)NLM000017701 |x 1460-2091 |7 nnns |
| 773 | 1 | 8 | |g volume:79 |g year:2024 |g number:1 |g day:03 |g month:01 |g pages:172-178 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/jac/dkad362 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 79 |j 2024 |e 1 |b 03 |c 01 |h 172-178 | ||